Results 251 to 260 of about 7,203,866 (304)
Some of the next articles are maybe not open access.
Cardiology in Review, 2019
Long-acting basal insulins are used for the management of both type 1 and type 2 diabetes mellitus. Long-acting basal insulins were developed utilizing recombinant DNA technology and have been available since 2000 with the approval of insulin glargine U-100 followed by insulin detemir in 2005.
Kelsea, Gallegos Aragon +4 more
openaire +2 more sources
Long-acting basal insulins are used for the management of both type 1 and type 2 diabetes mellitus. Long-acting basal insulins were developed utilizing recombinant DNA technology and have been available since 2000 with the approval of insulin glargine U-100 followed by insulin detemir in 2005.
Kelsea, Gallegos Aragon +4 more
openaire +2 more sources
Diabetes care, 1999
Once daily injection of existing intermediate/long-acting insulin preparations does not provide a 24-h basal insulinemia in most patients. High variability, pronounced insulin peaks, and (as a result) a high risk of nocturnal hypoglycemia only poorly simulate normal physiology.
R H, Rosskamp, G, Park
openaire +1 more source
Once daily injection of existing intermediate/long-acting insulin preparations does not provide a 24-h basal insulinemia in most patients. High variability, pronounced insulin peaks, and (as a result) a high risk of nocturnal hypoglycemia only poorly simulate normal physiology.
R H, Rosskamp, G, Park
openaire +1 more source
Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir
Current Medical Research and Opinion, 2006To review intermediate- and long-acting insulins with specific emphasis on the newer insulin analogs.A MEDLINE search, in English, was conducted with a cut-off of June 30, 2006, using the terms 'NPH insulin', 'insulin analogs', 'insulin glargine', 'insulin detemir' and 'long-acting insulins'.
openaire +2 more sources
Prodrug approaches for the development of a long-acting drug delivery systems
Advanced Drug Delivery Reviews, 2023Kim A. Woodrow
exaly
Insulin glargine: a long-acting insulin for diabetes mellitus.
Issues in emerging health technologies, 2003Insulin glargine is a once-daily, biosynthetic, human insulin analogue. Some trials show that in patients with type 1 diabetes mellitus, insulin glargine offers an advantage in blood glucose control compared with NPH insulin. There is some evidence of decreased nocturnal and symptomatic hypoglycemia in patients receiving insulin glargine compared with ...
openaire +1 more source
Current trends in PLGA based long-acting injectable products: The industry perspective
Expert Opinion on Drug Delivery, 2022Omkara Swami Muddineti, Abdelwahab Omri
exaly
Insulin detemir (levemir), a new long-acting insulin.
The Medical letter on drugs and therapeutics, 2006The second basal insulin analog for type 1 and type 2 diabetes. How does it compare to NPH? And to glargine (Lantus).
openaire +1 more source
Clinically established biodegradable long acting injectables: An industry perspective
Advanced Drug Delivery Reviews, 2020Rui W M Krause +2 more
exaly
Long-acting drugs and formulations for the treatment and prevention of HIV infection
International Journal of Antimicrobial Agents, 2021Susan Swindells +2 more
exaly